6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases
作者:Andrew M. Thompson、Adrian Blaser、Brian D. Palmer、Robert F. Anderson、Sujata S. Shinde、Delphine Launay、Eric Chatelain、Louis Maes、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、William A. Denny
DOI:10.1016/j.bmcl.2017.03.069
日期:2017.6
its assessment in an acute Mycobacterium tuberculosis mouse model, alongside the corresponding oxazole (48), but the latter proved to be more efficacious. In vitro screening against kinetoplastid diseases revealed that nitroimidazothiazoles were inactive versus leishmaniasis but showed interesting activity, superior to that of the nitroimidazooxazoles, against Chagas disease. Overall, "thio-delamanid"
为了寻求抗结核药物类前驱体(PA-824)的备份,我们研究了未开发的6-硝基-2,3-二氢咪唑并[2,1-b] [1,3]-噻唑和相关的-恶唑。硝基咪唑并噻唑是由2-溴-4-硝基咪唑通过与取代的噻喃和二异丙基乙胺加热而高产率制备的。这两个结构类别的等效实例提供了可广泛比较的MIC,其中2-甲基取代和优选的芳氧基甲基侧链扩展;尽管,S-氧化的噻唑类药物对结核病无效。联苯噻唑的有利的微粒体稳定性数据(45)与相应的恶唑(48)一起在急性结核分枝杆菌小鼠模型中进行了评估,但事实证明后者更为有效。体外对动素体疾病的筛选显示,硝基咪唑并噻唑对利什曼病无活性,但对查加斯病表现出有趣的活性,优于硝基咪唑并恶唑。总体而言,“硫磺-德拉曼尼德”(49)被认为是最佳的铅。